Eculizumab discontinuation in atypical haemolytic uraemic syndrome : TMA recurrence risk and renal outcomes
Ariceta Iraola, Gema (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Fakhouri, Fadi (CHU de Nantes)
Sartz, Lisa (Skåne University Hospital (Suècia))
Miller, Benjamin (Alexion Pharmaceutical (Estats Units d'Amèrica))
Nikolaou, Vasilis (Parexel International (Regne Unit))
Cohen, David (Columbia University Medical Center)
Siedlecki, Andrew M. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica))
Ardissino, Gianluigi (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	Eculizumab modifies the course of disease in patients with atypical haemolytic uraemic syndrome (aHUS), but data evaluating whether eculizumab discontinuation is safe are limited. Patients enrolled in the Global aHUS Registry who received ≥1 month of eculizumab before discontinuing, demonstrated haematologic or renal response prior to discontinuation and had ≥6 months of follow-up were analysed. The primary endpoint was the proportion of patients suffering from thrombotic microangiopathy (TMA) recurrence after eculizumab discontinuation. Additional endpoints included: estimated glomerular filtration rate changes following eculizumab discontinuation to last available follow-up; number of TMA recurrences; time to TMA recurrence; proportion of patients restarting eculizumab; and changes in renal function. We analysed 151 patients with clinically diagnosed aHUS who had evidence of haematologic or renal response to eculizumab, before discontinuing. Thirty-three (22%) experienced a TMA recurrence. Univariate analysis revealed that patients with an increased risk of TMA recurrence after discontinuing eculizumab were those with a history of extrarenal manifestations prior to initiating eculizumab, pathogenic variants or a family history of aHUS. Multivariate analysis showed an increased risk of TMA recurrence in patients with pathogenic variants and a family history of aHUS. Twelve (8%) patients progressed to end-stage renal disease after eculizumab discontinuation; seven (5%) patients eventually received a kidney transplant. Forty (27%) patients experienced an extrarenal manifestation of aHUS after eculizumab discontinuation. Eculizumab discontinuation in patients with aHUS is not without risk, potentially leading to TMA recurrence and renal failure. A thorough assessment of risk factors prior to the decision to discontinue eculizumab is essential.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Anaemia ; GFR ; Haemoglobin ; Thrombosis ; Thrombotic microangiopathy
Publicat a:	Clinical Kidney Journal, Vol. 14 (january 2021) , p. 2075-2084, ISSN 2048-8513

DOI: 10.1093/ckj/sfab005
PMID: 35261761

10 p, 4.0 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats